Oncology
Laboratory/Clinical Translational Research
Immunohistochemical Study of Glypican 3 in Thyroid CancerYamanaka K.a · Ito Y.b · Okuyama N.a · Noda K.a · Matsumoto H.a · Yoshida H.b · Miyauchi A.b · Capurro M.c · Filmus J.c · Miyoshi E.aaDepartment of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, and bDepartment of Surgery, Kuma Hospital, Kobe, Japan; cDivison of Molecular and Cell Biology, Sunnybrook and Women’s College Health Science Center, and Department of Medical Biophysics, University of Toronto, Toronto, Ont., Canada
|
|
Oncology 2007;73:389–394
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: October 10, 2007
Accepted: November 15, 2007
Published online: May 30, 2008
Issue release date: June 2008
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
In 123 patients with thyroid cancer, expression of glypican 3 (GPC3) was immunohistochemically investigated in tissue samples and the biological significance of GPC3 in thyroid cancer was examined. GPC3 was scarcely expressed in the normal thyroid gland, but was dramatically enhanced in certain types of cancers: 100% in follicular carcinoma (20/20 cases) and 70% in papillary carcinoma (48/69 cases). Expression of GPC3 in follicular carcinoma was significantly higher than that of follicular adenoma (p < 0.0019). In contrast, GPC 3 was not expressed in 17 cases of anaplastic carcinoma. A high expression of GPC3 mRNA was confirmed in cancer lesions, which were strongly positive for immunohistochemical staining. In 69 cases of papillary carcinoma, GPC3 was expressed at an early stage, suggesting that GPC3 expression in thyroid cancer is an early event in developing papillary carcinoma. Further studies are required to determine biological functions and molecular mechanisms underlying the upregulation of GPC3 in thyroid cancer.
© 2008 S. Karger AG, Basel
Related Articles:
References
- Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729–777.
-
Filmus J, Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest 1999;108:497–501.
External Resources
- Filmus J, Church J, Buick RN: Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol 1988;8:4243–4249.
- Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16–25.
- Neri G, Gurrieri F, Zanni G, Lin A: Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279–283.
- Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, Büchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558–564.
- Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455–465.
- Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M: Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003;94:259–262.
- Capurro MI, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89–97.
- Nakasura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, Nishimura Y: Identification of glypican-3 as a novel marker for melanoma. Clin Cancer Res 2004;10:6612–6621.
- Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y: Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006;66:2414–2422.
- Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006;12:2689–2697.
-
Faggin JA: Molecular genetics of tumors of thyroid follicular cells; in Braverman LE, Utiger RD (eds): The Thyroid, ed 8. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 886–898.
- Metaye T, Kraimps JL, Goujon JM, Fernandez B, Quellard N, Ingrand P, Barbier J, Begon F: Expression, localization and thyrotropin regulation of cathepsin D in thyroid tissues. J Clin Endocrinol Metab 1997;82, 3383–3388.
- Xu XC, el-Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 1995;147:815–822.
- Aratake Y, Kotani T, Tamura K, Araki Y, Kuribayashi T, Konoe K, Ohtaki S: Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. Am J Clin Pathol 1991;96:306–310.
- Sakamoto A, Kasai N, Sugano H: Poorly differentiated carcinoma of the thyroid. A clinicopathological entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983;52:1849–1855.
- Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
- Filmus J: Glypicans in growth control and cancer. Glycobiology 2001;11:19R–23R.
- Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR: Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000;19:410–416.
- Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Cappuro M, Brody JS, Lange J, D’Armiento JM, Rothman PB, Powell CA: The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 2003;29:694–701.
- Xiang YY, Ladeda V, Filmus J: Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408–7412.
- Lin H, Huber R, Schlessinger D, Morin PJ: Frequent silencing of the GPC3 in ovarian cancer cell lines. Cancer Res 1999;59:807–810.
-
Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002;26:336–372.
External Resources
- Lin X: Functions of heparan sulfate proteoglycans in cell signaling during development. Development 2004;131:6009–6021.
- Song HH, Shi W, Xiang YY, Filmus J: The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 2005;280:2116–2125.
- Capurro MI, Xiang YY, Lobe C, Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245–6254.
- Zhang L, David G, Esko JD: Repetitive Ser-Gly sequences enhance heparan sulfate assembly in proteoglycans. J Biol Chem 1995;270:27127–27135.
- Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D: Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241–247.
Article / Publication Details
First-Page Preview
Received: October 10, 2007
Accepted: November 15, 2007
Published online: May 30, 2008
Issue release date: June 2008
Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 2
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
